presentation on DATA INTEGRITY which I feel that it is useful for the Pharmaceutical quality. If anyone require a copy please feel free to contact me.

1. Page 1
DATA INTEGRITY
Monday, April 27, 2015
"This presentation is compiled from resources available on the world wide web.
“Drug Regulations” is a non profit organization which provides free online resource
to the Pharmaceutical Professional. Visit http://www.drugregulations.org for latest
information from the world of Pharmaceuticals.”

2. Page 2
DATA INTEGRITY
Data Integrity is assuming greater
importance in cGMP’s.
Quality of raw materials, in process
materials and finished goods can not be
assured with out data integrity.
Data integrity issues are 21 CFR Part 11 and
severe CGMP violations.

3. Page 3
DATA INTEGRITY
If the integrity of laboratory data is
compromised.
o Products may not comply with regulatory
authorization terms.
o Products can not be released for sale.
In recent past FDA has Increased its focus on
data integrity and reliability.
Similarly MHRA and Other regulatory bodies
have increased focus on data integrity.

4. Page 4
DATA INTEGRITY
Inspectors are examining data based on
multiple regulations and standards.
o CGMP
o Good Laboratory Practices (GLP),
o Good Clinical Practices (GCP) and
o The Application Integrity Policy.

5. Page 5
DATA INTEGRITY
“Guilty until proven innocent” approach.
Historical approaches based on technical
justification and scientific rationale not
adequate.
Emphasis on providing evidence that the
analytical results are not fraudulent.

6. Page 6
What is DATA INTEGRITY?
Data integrity is the assurance that data
records are accurate, complete, intact and
maintained within their original context,
including their relationship to other data
records.
This definition applies to data recorded in
electronic and paper formats or a hybrid of
both.

7. Page 7
Ensuring DATA INTEGRITY:
Protecting original data from
Accidental modification
Intentional Modification
Falsification
Deletion

8. Page 8
DATA INTEGRITY:
Data Integrity key to
Reliable and trust worthy records
Record that will withstand scrutiny during
regulatory inspections.
According to FDA, which uses the acronym
ALCOA, data need to be “attributable,
legible, contemporaneous, original, and
accurate.”

9. Page 9
Data Integrity: ALCOA
Attributable Legible
Contempora
neous Original
Accurate

10. Page 10
Revealing list of DATA INTEGRITY observation in
FDA Audits:
“…..trial injections…..”
“results failing specifications are retested
until acceptable results are obtained….”
“…..over-writing electronic raw data…..”
“…….OOS not investigates per XYZ SOP….”
“……appropriate controls not established…..”
“……records are not completed
contemporaneously…”
“….observed back-date entry in logbooks.”

11. Page 11
INTEGRITY issue 1:
A) This is an Integrity issue

12. Page 12
INTEGRITY issue 2:

13. Page 13
INTEGRITY as per FDA:

14. Page 14
DATA INTEGRITY:
Data integrity is the assurance that data a consistent
,accurate , reliable and accessible
Data
Assuring
Accuracy
Completeness
Consistency
Reliable
Accidental-Un intentional
Unauthorized-Malicious
Generating
Transforming
Maintaining
Entire life cycle
NOT
Altered
Destroyed
Modified

15. Page 15
Reasons:

16. Page 16
Reasons:

17. Page 17
EXAMPLE 2:

18. Page 18
DOUBT:

19. Page 19
DOUBT:

20. Page 20
DOUBT:

21. Page 21
DOUBT:

22. Page 22
Data Integrity Regulations:
FDA inspects for electronic data integrity
during the pre- and post market product
approval process.
21 CFR Part 11 commonly referred to as
the “data integrity regulation.” Four goals
listed by FDA.
Assess the industry’s comprehension or
continuing misinterpretations of Part
11.
Determine how firms are ensuring the
integrity of electronic records.
Extend scrutiny of data, quality-related
and computerized system validation-
related Form 483 inspectional
observations since 2007.

23. Page 23
Electronic & Paper Data:
Comparisons between secure electronic data
and data in paper format
For software compliant to 21 CFR Part
11 (9) & with appropriate technical
controls.
Electronic data are more secure, more
difficult to manipulate or change, and
any changes are easier to detect.
Changes to paper data, such as a
printed chromatogram, are simpler to
make, but much harder to detect.

24. Page 24
Electronic & Paper Data:
Comparisons between secure electronic data
and data in paper format.
Defining paper records as “raw data”
(the so-called typewriter rule) does not
satisfy the predicate rules.
Printed paper copy of the
chromatogram will not be considered a
true copy.
Although this comment was made
about chromatographic data, the
principles have much wider
implications.

25. Page 25
Thank you very much your valuable time!